Company: HURA
Filing Date: 2025-04-01
Form Type: 425
Source: 0001193125-25-069713
Chunk: 6

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-04-01
Form: 425
Chunk 6
---
2025                                           |
|:--------|:----|:-----------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: April 1, 2025 |     | By: |     | TUHURA BIOSCIENCES, INC.                  
 /s/ Dan Dearborn                          |
|:--------------------|:----|:----|:----|:------------------------------------------|
|                     |     |     |     | Name: Dan Dearborn Title: Chief Financial 
 Officer                                   |

Exhibit 99.1

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Phase 3 IFx-2.0accelerated approval trial as adjunctive therapy with Keytruda ®

(pembrolizumab) in 1 stline therapy for advanced Merkel cell carcinoma (MCC)

planning to initiate enrollment in Q2 2025

MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA

Acquisition of Kineta’s Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025

Expanded discovery team for first-in-classimmune modulating Antibody Drug or Peptide Conjugate Program

TAMPA, FL, April 1, 2025 —TuHURA Biosciences, Inc. (NASDAQ:HURA)
(“TuHURA” or the “Company”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a
corporate update.

“2024 was a transformative year for TuHURA. We became a NASDAQ-listed Company, raised capital to meet FDA’s manufacturing
requirements to initiate our Phase 3 program anticipated for Q2 as forecasted and entered into a definitive agreement for, what we believe, is a best-in-class VISTA
inhibiting antibody adding a Phase 2 program in AML to our development pipeline,“ commented James Bianco, President and CEO of TuHURA. “As we advance our late stage clinical programs in 2025 with the goal of completing enrollment in our
Phase 3 trial next year,